Search results for "Azoles"

showing 10 items of 899 documents

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

2012

Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a powerful inhibitor of bone resorption, already clinically available for the treatment of patients with osteolytic metastases. Recent data also suggest that ZOL, used in breast cancer, may provide more than just supportive care modifying the course of the disease, though the possible molecular mechanism of action is still unclear. As breast cancer is one of the primary tumours with high propensity to metastasize to the bone, we investigated, for the first time, differential gene expression profile on Michigan Cancer Foundation-7 (MCF-7) breast cancer cells tre…

medicine.medical_specialtyAngiogenesismedicine.medical_treatmentBlotting WesternAngiogenesis InhibitorsAntineoplastic AgentsBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionZoledronic AcidZOL FN1 TGF-b1 THBS-1 invasion breast cancerBone resorptionThrombospondin 1Transforming Growth Factor beta1breast cancerBreast cancerTGF-β1Internal medicineThrombospondin 1medicineHumansBone ResorptionCell ProliferationMatrigelDiphosphonatesFN1Gene Expression ProfilingImidazolesCancerOriginal ArticlesCell BiologyZOLBisphosphonateMicroarray Analysisinvasionmedicine.diseaseFibronectinsUp-RegulationGene Expression Regulation NeoplasticEndocrinologyZoledronic acidTHBS-1MCF-7 CellsCancer researchMolecular MedicineFemalemedicine.drug
researchProduct

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classmedicine.medical_treatmentAnastrozoleBreast NeoplasmsAnastrozolePactPersistence (computer science)Medication AdherenceEosinophilia–myalgia syndromeBreast cancerInternal medicineNitrilesmedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyAromatase inhibitorbusiness.industrySurrogate endpointHematologyMiddle AgedTriazolesmedicine.diseasePostmenopauseOncologyPatient ComplianceFemalebusinessAdjuvantmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect

2011

Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…

medicine.medical_specialtyApolipoprotein BTetrazolescilostazol atherogenic dyslipidemiaPhosphodiesterase 3 InhibitorsPeripheral Arterial Diseasechemistry.chemical_compoundDiabetes mellitusInternal medicineHumansMedicinePharmacology (medical)DyslipidemiasPharmacologymedicine.diagnostic_testbiologybusiness.industryCholesterolGeneral MedicineAtherosclerosismedicine.diseaseLipidsCyclic Nucleotide Phosphodiesterases Type 3Intermittent claudicationCilostazolCilostazolPostprandialEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinlipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileLipoproteinmedicine.drug
researchProduct

Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats

2017

Background The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats. Material and Methods 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariectomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and OVX / ZOL group underwent ovariectomy. After 12 weeks, rats from OVX / ZOL were injected with 0.04 mg/kg ZOL intravenously once a week for 6 weeks. The rats from CTRL and OVX groups were injected with 0.9% NaCl. Implants were placed in the left tibia. Afte…

medicine.medical_specialtyBone densityOvariectomyDentistryZoledronic AcidOsseointegration03 medical and health sciences0302 clinical medicineAbsorptiometry PhotonBone DensityOsseointegrationInternal medicineMedicineAnalysis softwareAnimalsTibiaRats WistarGeneral DentistryBone mineralDental ImplantsBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchSham surgeryImidazoles030206 dentistry:CIENCIAS MÉDICAS [UNESCO]RatsZoledronic acidEndocrinologyOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASOvariectomized ratSurgeryFemaleOral Surgerybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Antagonism by SR 48692 of mechanical responses to neurotensin in rat intestine.

1996

Abstract 1. The effects of SR 48692 on neurotensin (NT)-induced mechanical responses were investigated in rat duodenum and proximal colon by use of isometric, isovolumic preparations. 2. SR 48692 inhibited the relaxant responses to NT in duodenal circular and longitudinal muscle. It also antagonized the NT-induced contractile effects in duodenal circular muscle and in proximal colon (both muscular layers). 3. From Schild analysis and pA2 value for SR 48692 was 8.2 in tissues where NT induced relaxant effects and 7.5 in tissues where NT induced contractile effects and the slope of the regression line was not significantly different from unity, indicating competitive antagonism. 4. SR 48692 d…

medicine.medical_specialtyCarbacholColonDuodenumMuscle RelaxationNeuropeptideSubstance PBiologyPeptide hormoneIn Vitro Techniqueschemistry.chemical_compoundNorepinephrineInternal medicineIsometric ContractionmedicineAnimalsReceptors NeurotensinVasoconstrictor AgentsRats WistarReceptorNeurotensinPharmacologyMuscle SmoothRatsMuscle relaxationmedicine.anatomical_structureEndocrinologychemistryDuodenumQuinolinesPyrazolesmedicine.drugNeurotensinResearch ArticleBritish journal of pharmacology
researchProduct

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the …

2018

Summary Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as pr…

medicine.medical_specialtyCongenital cytomegalovirus infectionCytomegalovirusAntiviral AgentsLetermovirInternal medicinemedicineHumansIn patientGanciclovirLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMaribavirmedicine.diseaseTransplantationClinical trialHaematopoiesisInfectious DiseasesHematologic NeoplasmsCytomegalovirus InfectionsPractice Guidelines as TopicBenzimidazolesRibonucleosidesStem cellbusinessmedicine.drugThe Lancet. Infectious diseases
researchProduct

Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole

1988

Abstract The antihistamine and anticholinergic properties of mequitazine have been investigated and compared with those of clemizole. Both mequitazine and clemizole antagonized the effect of histamine in guinea-pig ileum competitively, the pA2 values calculated by Schild plot were 9.95 ± 0.44 for mequitazine and 10.54 ± 0.44 for clemizole. Mequitazine at 10−7 M produced a parallel shift of the dose-response curve to acetylcholine in the rat duodenum, clemizole and the lower doses of mequitazine failed to modify the effect of acetylcholine. The potency of mequitazine and clemizole as H1-histamine blockers is similar, but only mequitazine at highest concentration used showed anticholinergic a…

medicine.medical_specialtyDuodenummedicine.drug_classmedicine.medical_treatmentGuinea PigsPharmaceutical ScienceIn Vitro TechniquesBiologyParasympatholyticchemistry.chemical_compoundPhenothiazinesInternal medicinemedicineAnticholinergicAnimalsPotencyMequitazinePharmacologyParasympatholyticsMuscle SmoothRats Inbred StrainsAcetylcholineRatsClemizoleSchild regressionEndocrinologychemistryHistamine H1 AntagonistsBenzimidazolesAntihistamineHistamineHistamineMuscle Contractionmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation.

2000

Background —Angiotensin II (Ang II) plays a critical role in the development of vascular lesions in hypertension, atherosclerosis, and several renal diseases. Because Ang II may contribute to the leukocyte recruitment associated with these pathological states, the aim of the present study was to assess the role of Ang II in leukocyte–endothelial cell interactions in vivo. Methods and Results —Intravital microscopy of the rat mesenteric postcapillary venules was used. Sixty minutes of superfusion with 1 nmol/L Ang II induced a significant increase in leukocyte rolling flux (83.8±20.7 versus 16.4±3.1 cells/min), adhesion (11.4±1.0 versus 0.8±0.5 cells/100 μm), and emigration (4.0±0.7 versus …

medicine.medical_specialtyEndotheliumPyridinesLeukocyte RollingCell CommunicationReceptor Angiotensin Type 2LosartanReceptor Angiotensin Type 1Rats Sprague-DawleyDownregulation and upregulationPhysiology (medical)Internal medicineCromolyn SodiummedicineLeukocytesAnimalsEndotheliumReceptorAngiotensin II receptor type 1Receptors Angiotensinbusiness.industryAngiotensin IIImidazolesFlow CytometryAngiotensin IIRatsUp-RegulationEndothelial stem cellP-Selectinmedicine.anatomical_structureEndocrinologyLosartanCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

Inhibition of ovarian steroidogenesis by cyclic-GMP in a fly

2003

1479-6805 0022-0795; Previous investigations in the female blowfly Phormia regina have shown that 3-isobutyl-1-methylxanthine (IBMX), a broad spectrum inhibitor of phosphodiesterases (PDEs), fails to mimic the steroidogenic effects of cAMP on ovaries, although it efficiently increases the concentrations of this second messenger. In this study, experiments carried out to clear up this contradiction demonstrated that IBMX, besides its effect on cAMP, also increased cGMP concentrations in blowfly ovary and that these two cyclic nucleotides controlled ovarian steroidogenesis antagonistically. In particular, a selective inhibitor of cGMP-specific PDEs, unlike IBMX, had a very strong negative eff…

medicine.medical_specialtyIBMXIndolesPhosphodiesterase InhibitorsEndocrinology Diabetes and MetabolismCarbazolesOvarySteroid biosynthesisBiologychemistry.chemical_compoundEndocrinologyAlkaloidsOrgan Culture TechniquesInternal medicine1-Methyl-3-isobutylxanthinemedicineCyclic AMPCyclic GMP-Dependent Protein KinasesAnimalsAutocrine signallingCyclic GMPAdenineDipteraColforsinOvaryPhosphodiesteraseBrainEcdysteroidsStimulation ChemicalEndocrinologymedicine.anatomical_structurechemistrySecond messenger systemQuinazolinesFemalePDE10ACalcium ChannelscGMP-dependent protein kinaseSignal Transduction
researchProduct

Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

2013

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…

medicine.medical_specialtyImmunologyArthritisLung biopsyGastroenterologyPulmonary function testingArthritis RheumatoidAntibodies Monoclonal Murine-DerivedPatient Education as TopicUsual interstitial pneumoniaInternal medicinemedicineHumansImmunology and AllergyAntibodies BlockingPneumonitisLeflunomideClinical Trials as TopicTumor Necrosis Factor-alphabusiness.industryInterstitial lung diseaseIsoxazolesmedicine.diseaserespiratory tract diseasesMethotrexateAntirheumatic AgentsRheumatoid arthritisImmunologyLung Diseases InterstitialRituximabbusinessLeflunomidemedicine.drugExpert Review of Clinical Immunology
researchProduct